High methylation in the SPRY4 promoter region has been observed in patients with prostate cancer (67), colorectal cancer (68), and familial testicular cancer (69), leading to transcriptional inactivation of SPRY4 and promoting tumor occurrence and development. Here, SPRY4 is linked to colorectal cancer.